Virchows Archiv B

, 56:259 | Cite as

Complement activation in amyloid plaques in Alzheimer’s dementia

  • P. Eikelenboom
  • C. E. Hack
  • J. M. Rozemuller
  • F. C. Stam
Article

Summary

Amyloid plaques in Alzheimer’s dementia contain complement factors C1q, C4 and C3. In the present study we demonstrate complement activation in amyloid plaques using immunoenzymatical techniques and specific antibodies against subunits of individual complement components and activated complement products. Amyloid plaques contain C1q and activated C3 fragments (C3c and C3d, g) but no C1s and C3a. These findings demonstrate that the complement components are not passively bound to the amyloid plaque structures but are the result of an activation process. The role of complement activation in the genesis of senile plaques is discussed.

Key words

Alzheimer’s dementia Amyloid plaques Complement activation 

References

  1. Abraham CR, Selkoe DJ, Potter H (1988) Immunochemical identification of the serine protease inhibitor α1-antichymotrypsin in the brain amyloid deposits of Alzheimer’s disease. Cell 52:487–501PubMedCrossRefGoogle Scholar
  2. Alafuzoff I, Adolfsson R, Grundke-Iqbal I, Winblad B (1987) Blood-brain barrier in Alzheimer’s dementia and in nondemented elderly. Acta Neuropathol [Berl] 73:160–166CrossRefGoogle Scholar
  3. Eikelenboom P, Stam FC (1982) Immunoglobulins and complement factors in senile plaques: an immunohistoperoxidase study. Acta Neuropathol [Berl] 57:239–242CrossRefGoogle Scholar
  4. Eikelenboom P, Stam FC (1984) An immunohistochemical study in cerebrovascular and senile plaque amyloid in Alzheimer’s dementia. Virchows Arch [Cell Pathol] 46:17–25CrossRefGoogle Scholar
  5. Eikelenboom P, Scott JR, McBride PA, Rozemuller JM, Bruce ME, Fraser H (1987) No evidence for involvement of plasmaproteins or blood-borne cells in amyloid plaque formation in scrapie-affected mice. Virchows Arch [Cell Pathol] 53:251–256CrossRefGoogle Scholar
  6. Glenner G, Wong CW (1984) Alzheimer’s disease and Down’s syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 122:1131–1135PubMedCrossRefGoogle Scholar
  7. Hack CE, Paardekooper J, Smeenk RJT, Abbink J, Eerenberg AJM, Nuijens JH (1988) Disruption of the internal thioester bond in the third component of complement (C3) results in the exposure of neodeterminants also present on activation products of C3. J Immunol 141:1602–1609PubMedGoogle Scholar
  8. Ishii T, Haga S (1984) Immuno-electron-microscopic localisation of complements in amyloid fibrils of senile plaques. Acta Neuropathol [Berl] 63:296–300CrossRefGoogle Scholar
  9. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Müller-Hill B (1987) The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature 325:733–736PubMedCrossRefGoogle Scholar
  10. Kitaguchi N, Takahashi Y, Tokushima Y, Shiojiri S, Ito H (1988) Novel precursor of Alzheimer’s disease amyloid protein shows protease inhibitory activity. Nature 331:530–532PubMedCrossRefGoogle Scholar
  11. Lachmann PJ, Pangburn MK, Oldroyd RG (1982) Breakdown of C3 after complement activation. Identification of a new fragment, C3g, using monoclconal antibodies. J Exp Med 156:205–216PubMedCrossRefGoogle Scholar
  12. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82:4245–4249PubMedCrossRefGoogle Scholar
  13. Müller-Eberhard HJ, Schreiber RD (1980) Molecular biology and chemistry of the alternative pathway of complement. Adv Immunol 29:1–53PubMedCrossRefGoogle Scholar
  14. Nuijens JH, Huijbregts CCM, van Mierlo GM, Hack CE (1987) Inactivation of C1 inhibitor by proteases: demonstration by a monoclonal antibody of a neodeterminant on inactivated, non-complexed C1 inhibitor. Immunology 61:387–389PubMedGoogle Scholar
  15. Pangburn MK, Müller-Eberhard HJ (1980) Relation of a putative thioesterbond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med 152:1102–1119PubMedCrossRefGoogle Scholar
  16. Pangburn MK, Schreiber RD, Müller-Eberhard HJ (1981) Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J Exp Med 154:856–867PubMedCrossRefGoogle Scholar
  17. Pouplard A, Emile J (1985) New immunological findings in senile dementia. Interdiscipl Topics Geront 19:62–71Google Scholar
  18. Pouplard-Barthelaix A (1988) Immunological markers and neuropathological lesions in Alzheimer’s disease. In: Pouplard-Barthelaix A, Emile J, Christen Y (eds) Immunology and Alzheimer’s disease. Springer, Berlin Heidelberg New York Tokyo Hongkong, pp 7–16Google Scholar
  19. Ponte P, Gonzalez-DeWhitt P, Schilling J, Miller J, Hsu D, Greenberg B, Davis K, Wallace W, Lieberburg I, Fuller F, Cordell B (1988) A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors. Nature 331:525–527PubMedCrossRefGoogle Scholar
  20. Puchtler H, Sweat F, Levine H (1962) On the binding of Congo red by amyloid. J Histochem Cytochem 10:355–364Google Scholar
  21. Stam FC, Eikelenboom P (1985) Immunological study of cerebral senile amyloid (congophilic angiopathy and senile plaques). Interdiscipl Topics Geront 19:127–130Google Scholar
  22. Tamerius JD, Pangburn MK, Müller-Eberhard HJ (1985) Detection of a neoantigen on human C3bi and C3d by a monoclonal antibody. J Immunol 135:2015–2017PubMedGoogle Scholar
  23. Tanzi RE, McClatchey AI, Lamperti ED, Villa-Komaroff L, Gusella JF, Neve RL (1988) Protease inhibitor domain encoded by an amyloid precursor mRNA associated with Alzheimer’s disease. Nature 331:528–530PubMedCrossRefGoogle Scholar
  24. Ziccardi RJ, Cooper NR (1979) Active disassembly of the first complement component, C1, by Cl inactivator. J Immunol 123:788–792PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • P. Eikelenboom
    • 1
  • C. E. Hack
    • 3
  • J. M. Rozemuller
    • 2
  • F. C. Stam
    • 2
  1. 1.Department of PsychiatryFree UniversityAmsterdamThe Netherlands
  2. 2.Department of Neuropathology, Medical FacultyFree UniversityAmsterdamThe Netherlands
  3. 3.Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical ImmunologyUniversity of AmsterdamThe Netherlands

Personalised recommendations